Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents.
Pierre BramiQuentin FischerVincent PhamGabriel SeretOlivier VarenneFabien PicardPublished in: Journal of clinical medicine (2023)
Cardiovascular disease, including ischemic heart disease, is the leading cause of death worldwide, and percutaneous coronary interventions (PCIs) have been demonstrated to improve the prognosis of these patients on top of optimal medical therapy. PCIs have evolved from plain old balloon angioplasty to coronary stent implantation at the end of the last century. There has been a constant technical and scientific improvement in stent technology from bare metal stents to the era of drug-eluting stents (DESs) to overcome clinical challenges such as target lesion failure related to in-stent restenosis or stent thrombosis. A better understanding of the underlying mechanisms of these adverse events has led DESs to evolve from first-generation DESs to thinner and ultrathin third-generation DESs with improved polymer biocompatibility that seems to have reached a peak in efficiency. This review aims to provide a brief historical overview of the evolution of coronary DES platforms and an update on clinical studies and major characteristics of the most currently used DESs.
Keyphrases
- coronary artery disease
- coronary artery
- cardiovascular disease
- end stage renal disease
- ejection fraction
- aortic stenosis
- newly diagnosed
- chronic kidney disease
- healthcare
- physical activity
- pulmonary embolism
- stem cells
- peritoneal dialysis
- type diabetes
- prognostic factors
- minimally invasive
- cardiovascular events
- drug induced
- metabolic syndrome
- transcatheter aortic valve replacement
- adverse drug
- left ventricular
- mesenchymal stem cells
- bone marrow
- atrial fibrillation
- cardiovascular risk factors
- patient reported